SCHEMBL5753111

SCHEMBL5753111

Clc1cccc(CNc2nnc(CCc3cccnc3)c3ccccc23)c1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
MEN1 O00255 2/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
FLT1 P17948 2/20 0.51
CLK4 Q9HAZ1 1/20 0.47
NPC1 O15118 2/20 0.46
APP P05067 1/20 0.46
PDE5A O76074 4/20 0.45
ACP1 P24666 1/20 0.44
KDR P35968 1/20 0.44
GRM4 Q14833 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5753555 0.78 FLT1 (0.80) KMT2AMEN1FLT1KDR
SCHEMBL4814640 0.75 FLT1 (0.48) GAAMAPTFLT1
SCHEMBL14267794 0.75 FLT1 (0.65) KMT2AMEN1FLT1CLK4KDR
SCHEMBL5793780 0.75 NPC1 (0.57) KMT2AMEN1GAAMAPTNPC1
SCHEMBL9807640 0.74 FLT1 (0.77) KMT2AMEN1MAPTFLT1PDE5A
SCHEMBL5754939 0.73 KDR (0.65) KMT2AMEN1MAPTFLT1KDR
SCHEMBL1651296 0.73 FLT1 (0.79) KMT2AMEN1FLT1KDR
SCHEMBL5753928 0.72 KDR (0.70) KMT2AMEN1MAPTFLT1KDR
SCHEMBL7279378 0.70 MEN1 (0.84) KMT2AMEN1GAAMAPTCLK4
SCHEMBL27466738 0.70 PDE5A (0.67) KMT2AMEN1FLT1PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1165085-B1 PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES NOVARTIS AG (CH) 2006-06-14 EP claimed
US-7329660-B2 Phthalazine derivatives for treating inflammatory diseases NOVARTIS AG (CH) 2008-02-12 US disclosed
US-7329660-B2 Phthalazine derivatives for treating inflammatory diseases NOVARTIS AG (CH) 2008-02-12 US disclosed